Medtronic plc (MDT)

From the record

Medtronic plc's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Medtronic plc's 10 filed years say what it did: revenue went from $30 billion in fiscal 2017 to $36 billion in fiscal 2026, up 2.3% a year; it rose in 7 of 9 years; the deepest fall was 5% from fiscal 2019 to fiscal 2020; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2026-04-24, Medtronic plc's diluted share count shrank about 1.1% a year, and dividends and buybacks returned about 82% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 18 sales (3 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-04 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2026-04-24, Medtronic plc earned about 10 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 25 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 47 cents per dollar of assets, and net share issuance: its share count shrank 0.1% over the year (the filed statements).

From the record

Medtronic plc's standing among 24 graded names in its industry family: revenue of $36 billion in fiscal 2026 ranks in the top 2% by size; a net margin of 13.2% ranks in the top 15%; revenue growth of 5.2% a year over the last 3 filed years ranks in the bottom 34% (its annual reports).

From the record

Medtronic plc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Martha, Geoffrey (Chairman and CEO, as filed), filing under that title since 2020-08-03, 6.3 years (top 14% of its family); the 21 officers and directors filing in the last fifteen months have been on the record a median of 3.4 years (bottom 44%); 12 officer or director changes were reported on Form 8-K since 2023-11-13, against the 21 people in charge now (top 50%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Medtronic plc's room to grow, from the newest filed statements (fiscal 2026): cash of $1.9 billion against debt of $26 billion leaves -26% of its assets as net cash, bottom 10% of its family; cash from operations less capital spending is 14.9% of revenue (top 11%); a gross margin of 65% (top 37%); research spending of 7.9% of revenue (bottom 34%) (its annual report).

From the record

Medtronic plc's growth drivers, from the filed years to fiscal 2026: revenue grew 5.2% a year over the last three filed years against 2.3% over all 10, speeding up (top 24% of its family); the newest year grew 8.5% (bottom 41%); research spending grew 2.1% a year (bottom 42%); capital spending grew 9.3% a year (top 44%) (its annual reports). Medtronic plc reported 6 lines of business in fiscal 2025: Total Reportable at $33 billion, Cardiovascular at $12 billion, Neuroscience Group at $9.8 billion, and 3 more. 3 of 6 grew in the latest filed year, and the largest line is 50% of revenue (its annual report).

From the record

Medtronic plc's newest year against its own record: revenue of $36 billion in fiscal 2026 came in 4.6% above the $35 billion its prior three years' pace pointed to (top 40% of its family); net income of $4.8 billion against a prior three-year average of $4.0 billion (top 43%); a net margin of 13.2% against 12.4% before (bottom 33%) (its annual reports).